Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a large increase in short interest in November. As of November 15th, there was short interest totalling 736,700 shares, an increase of 51.3% from the October 31st total of 487,000 shares. Based on an average trading volume of 112,200 shares, the days-to-cover ratio is currently 6.6 days. Approximately 3.9% of the shares of the stock are short sold.

Vigil Neuroscience Price Performance

Shares of VIGL traded up $0.17 during trading hours on Friday, hitting $2.47. 336,264 shares of the stock were exchanged, compared to its average volume of 236,055. Vigil Neuroscience has a fifty-two week low of $2.08 and a fifty-two week high of $6.06. The business has a 50-day moving average of $3.42 and a 200-day moving average of $3.64. The firm has a market capitalization of $100.97 million, a P/E ratio of -1.16 and a beta of 1.92.

Institutional Trading of Vigil Neuroscience

Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new stake in shares of Vigil Neuroscience during the 2nd quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience during the 2nd quarter worth approximately $87,000. Renaissance Technologies LLC increased its stake in shares of Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after acquiring an additional 11,536 shares in the last quarter. Walleye Capital LLC increased its stake in shares of Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after acquiring an additional 92,217 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in shares of Vigil Neuroscience during the 3rd quarter valued at $442,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VIGL has been the subject of several research reports. JMP Securities reiterated a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday. Wedbush raised their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Guggenheim cut their price target on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a report on Friday, November 8th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, Vigil Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.